Stock Ratings / Industrials / CUVL / dividends

CDTG (26) DXST (47) FERG (69) NKLR (32) ⌘ Pro Terminal →

Clinuvel Pharmaceuticals Limited (CUVL) Dividend Safety Gauge & 10-Year DRIP Compounder

$5.15 +1.58% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.15

Clinuvel Pharmaceuticals Limited (CUVL) carries a Roarable Rating of C+ (Hold) with 66/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY) →

ROARABLE C+ • HOLD / WATCH Cap $257.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $5.15 (+0.09%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 16/20 (B+) • 44.3% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 66/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.4% avg 90D alpha vs SPY • 56.0% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+3.7% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CUVL)Realized 20D OHLCV Swing Band: ±8.5%

Deterministic 5-Pillar Attribution (66/100 Composite)

🔍 WHY CUVL SCORES 66/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+16/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 44.3% FCF Margin ($27.1M FCF) & 81.2% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▼ #1 Drag / Risk Factor: Whale & Options Positioning8/20 pts (-12 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-12 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B+$5.59-6.3% Next Q

Q2 (-2Q)

Grade B$5.24-5.7% Next Q

Q3 (-1Q)

Grade B-$4.94+4.3% Next Q

Current

Grade C+$5.15+1.4% Hist 90D α

Trajectory: B+ (74) → C+ (66)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the CUVL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 66/100 (C+) score, CUVL faces multiple-compression risk if 11.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 78.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.83) or 200D SMA ($6.79) invalidates the momentum regime and cuts Target Base ($5.34) toward Bear Floor ($4.17).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CUVL• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CUVL Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 66%NO 34%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

2.46% Total Yield

0.66% Cash ($0.03/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

88/100 • FORTRESS PAYOUT

FREE CASH FLOW PAYOUT RATIO

14% of FCF

8 consecutive years of payout growth

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,908

Est. Year-10 Shareholder Yield: $441/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.2K

Yr 2

$11.9K

Yr 3

$12.6K

Yr 4

$13.4K

Yr 5

$14.2K

Yr 6

$15.0K

Yr 7

$15.9K

Yr 8

$16.9K

Yr 9

$17.9K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in CUVL & A-Rated Leaders

✓12-month Bull/Base/Bear fair-value walkthrough on CUVL and its top sector peer
✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
✓Includes nightly RQD rating-change & forensic signal email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CUVL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -23.13%📐 HORIZONTAL RANGE

2026-10-30O $6.11H $6.11L $4.95C $5.15VOL 5.2K

RES: $8.22SUP: $4.64SMA50: $5.83SMA200: $6.79

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CUVL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CUVL Butterfly Map → + Track CUVL →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

0.9%/yr Implied 5Y Growth

vs. +5.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CUVL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CUVL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CUVL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CUVL)

Industrials Rank #108 of 485 ⚔️ CDTG vs CUVL Full Matrix →

1. Head-to-Head Industrials Peer Comparison (CUVL vs. CDTG, DXST, FERG, NKLR)

Industry: Miscellaneous (4 Tracked Issuers)

Across 485 tracked Industrials securities in the Roarable RQD universe, Clinuvel Pharmaceuticals Limited (CUVL) ranks #108 by composite RQD confidence (66/100, grade C+) and #335 by equity capitalization ($257.8M). Within this direct 5-issuer industry benchmark cohort, CUVL leads on earnings valuation at 11.1x trailing P/E, while FERG leads on capital efficiency and profitability with 22.2% ROIC and 30.7% gross margin. FERG currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with CUVL at 66/100 (C+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CUVL ACTIVE Clinuvel Pharmaceuticals Limited	C+	66/100	11.1x	81.2%	—	+1.58%	$257.8M	Benchmark Subject
CDTG CDT Environmental Technology Investment Holdings Limited	E	26/100	—	41.5%	-30.1%	-7.84%	$2.8M	/cdtg-vs-cuvl →
DXST Decent Holding Inc (Class A)	D	47/100	—	26.2%	—	+2.68%	$2.4M	/dxst-vs-cuvl →
FERG Ferguson Enterprises Inc.	C+	69/100	25.1x	30.7%	22.2%	+4.21%	$46.52B	/ferg-vs-cuvl →
NKLR Terra Innovatum Global N.V.	E	32/100	—	—	-35.0%	-2.51%	$257.5M	/nklr-vs-cuvl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001290877

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Clinuvel Pharmaceuticals Limited (CUVL) reported GAAP revenue of $61.1M (+5.5% vs. FY2024 revenue of $57.9M ) , GAAP net income of $23.1M, operating cash flow of $27.3M, and free cash flow of $27.1M (+34.9% YoY). On the balance sheet, CUVL closed FY2025 with $0 in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$61.1M	$23.1M	$27.3M	$27.1M	—	—
FY2024 (FY)	2024-06-30	$57.9M	$23.3M	$23.8M	$20.1M	—	—

3. CUVL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CUVL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Clinuvel Pharmaceuticals Limited (NASDAQ: CUVL) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 66/100 at a spot price of $5.15 (+1.58% 1D, market cap $257.8M). Pillar breakdown: Fundamental Cash Engine 16/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 485 tracked Industrials issuers, CUVL ranks #108 in composite RQD confidence.

How does CUVL compare to CDTG and DXST in the Industrials sector?

Within the Industrials sector (Miscellaneous), CUVL carries a Roarable C+ (66/100 RQD), trailing P/E of 11.1x, gross margin of 81.2%, and ROIC of —. By comparison, CDTG (CDT Environmental Technology Investment Holdings Limited) holds a E grade (26/100 RQD, P/E N/A, ROIC -30.1%, cap $2.8M) and DXST (Decent Holding Inc (Class A)) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $2.4M). Among the 5-stock peer group, CUVL leads on earnings multiple (11.1x) while FERG leads on capital efficiency (22.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CUVL?

Per CUVL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001290877), Clinuvel Pharmaceuticals Limited generated $61.1M in revenue (+5.5% YoY), $23.1M in net income, and $27.1M in free cash flow against $0 in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (81% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CUVL trading relative to its 50-day, 200-day, and 52-week technical levels?

CUVL last traded at $5.15 (+1.58% on volume of 8,165 shares), positioning the stock -11.66% below its 50-day simple moving average ($5.83) and -24.15% below its 200-day simple moving average ($6.79). Across its 52-week range of $4.88 to $8.92, CUVL sits at the 6.7% percentile with a 14-day RSI of 37.7 (NEUTRAL RANGE) and an implied next-earnings move of ±8.5% ($4.71 to $5.59).

CUVL Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does CUVL pay a dividend and is it safe?

Clinuvel Pharmaceuticals Limited (CUVL) offers a 0.66% cash dividend yield ($0.03 annualized) and 2.46% total shareholder yield including buybacks. Roarable rates its payout coverage as FORTRESS PAYOUT.

Direct Sub-Reports: CUVL RQD Cockpit CUVL 12M Forecast CUVL Earnings & Move CUVL Dividends & DRIP CUVL Insiders & 13F CUVL Whale Options CUVL Profit Sankey CUVL News & Why